Takeda Pharmaceutical Company Limited Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
Takeda Pharmaceutical Company Limited (TAK) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -JPY 61.30 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2025-06-25
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|
| 2025-03-31 | -61.30B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | -101.93B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | -339.09B JPY 20-F · filed 2025-06-25 |
| 2022-03-31 | -145.28B JPY 20-F · filed 2024-06-26 |
| 2021-03-31 | 316.11B JPY 20-F · filed 2023-06-28 |
| 2020-03-31 | -43.34B JPY 20-F · filed 2022-06-29 |
| 2019-03-31 | 439.02B JPY 20-F · filed 2021-06-29 |
| 2018-03-31 | -41.71B JPY 20-F · filed 2020-06-24 |
| 2017-03-31 | -104.43B JPY 20-F · filed 2019-06-27 |